Advertisement
Advertisement

SKYE

SKYE logo

Skye Bioscience, Inc. Common Stock

0.98
USD
Sponsored
+0.02
+2.08%
Jan 30, 13:02 UTC -5
Open

SKYE Earnings Reports

Positive Surprise Ratio

SKYE beat 5 of 9 last estimates.

56%

Next Report

Date of Next Report
Mar 18, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.30
Implied change from Q3 25 (Revenue/ EPS)
--
/
-6.25%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+25.00%

Skye Bioscience, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, SKYE reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.33 USD, resulting in a 5.66% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.82% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.30 USD, with revenue projected to reach -- USD, implying an decrease of -6.25% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Skye Bioscience, Inc. Common Stock reported EPS of -$0.32, beating estimates by 5.66%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.82%, changed from $1.42 before the earnings release to $1.46 the day after.
The next earning report is scheduled for Mar 18, 2026.
Based on 10 analysts, Skye Bioscience, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement